Emerald Advisers’s Akebia Therapeutics AKBA Stock Holding History

Emerald Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-42,910	Closed	-$554K	–	321
2015 Q4	$554K	Hold	42,910	–	–	0.03%	289
2015 Q3	$415K	Hold	42,910	–	–	0.02%	305
2015 Q2	$442K	Hold	42,910	–	–	0.02%	296
2015 Q1	$354K	Buy	+42,910	New	+$457K	0.02%	297

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Advisers's AKBA Position: Q1 2016 in Review

Emerald Advisers sold out of Akebia Therapeutics (AKBA) in Q1 2016, closing a stake of 42,910 shares — an estimated $554K sold.

Emerald Advisers first reported a position in AKBA in Q1 2015 and held it in 4 quarters. The position peaked at $554K in Q4 2015. 91 funds tracked by Wall St. Rank hold AKBA as of Q1 2016.

Emerald Advisers reported no remaining Akebia Therapeutics position as of Q1 2016 after selling out during the quarter.
Emerald Advisers sold 42,910 Akebia Therapeutics shares in Q1 2016, an estimated $554K.
Emerald Advisers first reported a position in Akebia Therapeutics in Q1 2015 and held it in 4 quarters.
Emerald Advisers's Akebia Therapeutics position peaked at $554K in Q4 2015.
91 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2016.

Based on Emerald Advisers's 13F filing for Q1 2016, filed 28 Apr 2016.